# A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

> **NCT00211276** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** ONTAK (denileukin diftitox)

## Key facts

- **NCT ID:** NCT00211276
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-01
- **Final completion:** 2007-02
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2012-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211276, "A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00211276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*